$AIMD
Ainos, Inc. Stock $aimd

$aimd Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000165495422015091 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$1.038M	$1.758M	$363.1K
YoY Change	3831.93%	384.17%	188989.58%
Cost Of Revenue	$578.2K	$1.176M	$103.6K
YoY Change	5806.13%	1034.75%	84158.54%
Gross Profit	$459.8K	$581.7K	$259.4K
YoY Change	2668.33%	124.25%	375862.32%
Gross Profit Margin	44.3%	33.1%	71.45%
Selling, General & Admin	$787.5K	$6.569M	$796.0K
YoY Change	341.96%	725.32%	147.84%
% of Gross Profit	171.27%	1129.23%	306.83%
Research & Development	$1.799M	$1.835M	$646.8K
YoY Change	41.22%	183.67%
% of Gross Profit	391.21%	315.4%	249.33%
Depreciation & Amortization	$1.225M	$1.229M
YoY Change
% of Gross Profit	266.48%	211.3%
Operating Expenses	$2.586M	$8.404M	$1.443M
YoY Change	78.12%	482.5%	349.24%
Operating Profit	-$2.127M	-$7.822M	-$1.183M
YoY Change	48.15%	561.03%	268.55%
Interest Expense	-$8.220K	$515.00	$23.52K
YoY Change	-11.9%	-97.81%	-1168.61%
% of Operating Profit
Other Income/Expense, Net	$3.800K	$10.34K	$1.443M
YoY Change		-99.28%	349.24%
Pretax Income	-$2.131M	-$7.822M	-$1.160M
YoY Change	47.5%	574.23%	258.85%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$2.131M	-$7.822M	-$1.160M
YoY Change	47.5%	574.23%	258.85%
Net Earnings / Revenue	-205.29%	-444.98%	-319.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.11	-$511.2K	-$122.2K
COMMON SHARES
Basic Shares Outstanding	20.01M shares	19.48M shares	142.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.853M	$2.417M	$706.9K
YoY Change	5.82%	241.92%	783.66%
Cash & Equivalents	$1.853M	$2.417M	$706.9K
Short-Term Investments
Other Short-Term Assets	$195.8K	$152.4K	$133.1K
YoY Change	-58.0%	14.53%	90.1%
Inventory	$595.2K	$698.3K	$173.7K
Prepaid Expenses
Receivables	$201.5K	$400.2K	$44.64K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.846M	$3.668M	$884.8K
YoY Change	28.33%	314.56%	460.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.376M	$1.351M	$39.96K
YoY Change	15.83%	3281.12%	1017.34%
Goodwill
YoY Change
Intangibles	$32.81M
YoY Change	-12.12%
Long-Term Investments
YoY Change
Other Assets	$80.68K	$116.4K	$1.795K
YoY Change	-7.87%	6386.07%
Total Long-Term Assets	$34.26M	$35.41M	$19.11M
YoY Change	-11.25%	85.33%	13230.18%
TOTAL ASSETS
Total Short-Term Assets	$2.846M	$3.668M	$884.8K
Total Long-Term Assets	$34.26M	$35.41M	$19.11M
Total Assets	$37.11M	$39.08M	$19.99M
YoY Change	-9.1%	95.47%	6536.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$578.6K
YoY Change			60.71%
Accrued Expenses	$1.212M	$1.383M	$31.98K
YoY Change	4128.33%	4223.3%
Deferred Revenue
YoY Change
Short-Term Debt	$884.0K	$884.0K	$2.185M
YoY Change	-75.38%	-59.55%	246.86%
Long-Term Debt Due	$376.5K	$376.5K	$2.000M
YoY Change	-88.86%	-81.17%
Total Short-Term Liabilities	$2.473M	$2.643M	$2.822M
YoY Change	-91.92%	-6.33%	161.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$8.100K	$12.51K	$35.29K
YoY Change	-73.23%	-64.55%
Total Long-Term Liabilities	$8.100K	$12.51K	$35.29K
YoY Change	-73.23%	-64.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.473M	$2.643M	$2.822M
Total Long-Term Liabilities	$8.100K	$12.51K	$35.29K
Total Liabilities	$2.481M	$2.656M	$2.857M
YoY Change	-91.9%	-7.05%	165.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.12M	-$21.98M	-$8.664M
YoY Change	138.56%	153.74%	50.11%
Common Stock	$200.1K	$194.8K	$1.424M
YoY Change	-86.14%	-86.33%	248.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.63M	$36.43M	$17.14M
YoY Change
Total Liabilities & Shareholders Equity	$37.11M	$39.08M	$19.99M
YoY Change	-9.1%	95.47%	6536.23%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$2.131M	-$7.822M	-$1.160M
YoY Change	47.5%	574.23%	258.85%
Depreciation, Depletion And Amortization	$1.225M	$1.229M
YoY Change
Cash From Operating Activities	-$615.4K	-$786.6K	-$526.2K
YoY Change	-9.6%	49.48%	209.54%
INVESTING ACTIVITIES
Capital Expenditures	-$35.97K	-$245.2K	$23.31K
YoY Change	-74.98%	-1152.04%
Acquisitions
YoY Change
Other Investing Activities	-$1.060K	$4.710K	-$43.38K
YoY Change	-116.04%	-110.86%
Cash From Investing Activities	$34.90K	-$240.5K	-$20.06K
YoY Change	-125.44%	1099.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.650K	1.646M	639.5K
YoY Change	-100.25%	157.38%	699.41%
NET CHANGE
Cash From Operating Activities	-615.4K	-786.6K	-526.2K
Cash From Investing Activities	34.90K	-240.5K	-20.06K
Cash From Financing Activities	-4.650K	1.646M	639.5K
Net Change In Cash	-585.2K	618.9K	93.25K
YoY Change	-155.93%	563.71%	-203.61%
FREE CASH FLOW
Cash From Operating Activities	-$615.4K	-$786.6K	-$526.2K
Capital Expenditures	-$35.97K	-$245.2K	$23.31K
Free Cash Flow	-$579.5K	-$541.4K	-$549.5K
YoY Change	7.9%	-1.49%	223.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001014763
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Local Phone Number LocalPhoneNumber	869-2986
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1751499	usd
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20011602	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2417147	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9625133	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19478270	shares
	aimd	Aggregate Fair Value Of Rsu AggregateFairValueOfRsu	1000000	usd
	us-gaap	Present Value Of Future Insurance Profits Weighted Average Amortization Period PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod	P2Y2M27D
	us-gaap	Maturity Of Time Deposits MaturityOfTimeDeposits	P1Y7M10D
	aimd	Grant Date Fair Value GrantDateFairValue	5900000.0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-20791
	dei	Entity Registrant Name EntityRegistrantName	AINOS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-1974352
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8880 Rio San Diego Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. 800
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92108
	dei	City Area Code CityAreaCode	858
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	400198	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2022Q3	us-gaap	Inventory Gross InventoryGross	698295	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	0	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	152406	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	466198	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	3668046	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2217697	usd
CY2022Q3	aimd	Intangible Assets Non Current IntangibleAssetsNonCurrent	33946391	usd
CY2021Q4	aimd	Intangible Assets Non Current IntangibleAssetsNonCurrent	37329191	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1350960	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1187702	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	116425	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	795958	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6569227	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	87571	usd
CY2022Q3	us-gaap	Assets Assets	39081822	usd
CY2021Q4	us-gaap	Assets Assets	40822161	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	376526	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3376526	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	884000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	213405	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1382721	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1004868	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	26000000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2643247	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30594799	usd
CY2022Q3	aimd	Operating Lease Liability Non Current OperatingLeaseLiabilityNonCurrent	12505	usd
CY2021Q4	aimd	Operating Lease Liability Non Current OperatingLeaseLiabilityNonCurrent	30255	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2655752	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30625054	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19478270	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9625133	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	194783	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	96251	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58491505	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20203972	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21984598	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10108916	usd
CY2022Q3	aimd	Translation Adjustment Liability TranslationAdjustmentLiability	-275620	usd
CY2021Q4	aimd	Translation Adjustment Liability TranslationAdjustmentLiability	5800	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	36426070	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10197107	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39081822	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40822161	usd
CY2022Q3	us-gaap	Revenues Revenues	1757774	usd
CY2021Q3	us-gaap	Revenues Revenues	363052	usd
	us-gaap	Revenues Revenues	2481602	usd
	us-gaap	Revenues Revenues	568164	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1176032	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	103638	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1536074	usd
	us-gaap	Cost Of Revenue CostOfRevenue	174395	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	581742	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	259414	usd
	us-gaap	Gross Profit GrossProfit	945528	usd
	us-gaap	Gross Profit GrossProfit	393769	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1834786	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	646798	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5047096	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	646798	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7748060	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2178969	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	8404013	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1442756	usd
	us-gaap	Operating Expenses OperatingExpenses	12795156	usd
	us-gaap	Operating Expenses OperatingExpenses	2825767	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7822271	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1183342	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11849628	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2431998	usd
CY2022Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-9821	usd
CY2021Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	23517	usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-45304	usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-9361	usd
CY2022Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	10336	usd
CY2021Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-285	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	19250	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2532	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	515	usd
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	23232	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-26054	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11893	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7821756	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1160110	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11875682	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2443891	usd
CY2022Q3	aimd	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.51
CY2021Q3	aimd	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.12
	aimd	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-1.03
	aimd	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.48
CY2022Q3	aimd	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	15301396	shares
CY2021Q3	aimd	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	9494468	shares
	aimd	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	11538013	shares
	aimd	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	5061160	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1160110	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11875682	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2443891	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-57674	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	6838	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-281420	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	6838	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7879430	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1153272	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12157102	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2437053	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6006320	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1780204	usd
CY2022Q3	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	30442959	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6076017	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7821756	usd
CY2022Q3	aimd	Translation Adjustment TranslationAdjustment	-57674	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	36426070	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	18205557	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	64752	usd
CY2021Q3	aimd	Translation Adjustment TranslationAdjustment	6838	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	17136360	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10197107	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1780204	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	30442959	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6162902	usd
	aimd	Translation Adjustment TranslationAdjustment	-281420	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	36426070	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-838278	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	139405	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	20000000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	64752	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	207533	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2443891	usd
	aimd	Translation Adjustment TranslationAdjustment	6838	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	17136360	usd
	us-gaap	Profit Loss ProfitLoss	-11875682	usd
	us-gaap	Profit Loss ProfitLoss	-2443891	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3608080	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1178693	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6162902	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	207533	usd
	aimd	Stock Issued For Compensationnoncash StockIssuedForCompensationnoncash	0	usd
	aimd	Stock Issued For Compensationnoncash StockIssuedForCompensationnoncash	139405	usd
	aimd	Loss On Disposal Of Fixed Property And Equipment LossOnDisposalOfFixedPropertyAndEquipment	0	usd
	aimd	Loss On Disposal Of Fixed Property And Equipment LossOnDisposalOfFixedPropertyAndEquipment	2227	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-400198	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-44643	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-698295	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2849	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	313792	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-81921	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	483660	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	470598	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2405741	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-569150	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	669792	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41581	usd
	aimd	Proceeds From Disposal Of Properties And Equipments ProceedsFromDisposalOfPropertiesAndEquipments	0	usd
	aimd	Proceeds From Disposal Of Properties And Equipments ProceedsFromDisposalOfPropertiesAndEquipments	36	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-4713	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	1795	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-665079	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43340	usd
	aimd	Payments Of Lease Liabilities PaymentsOfLeaseLiabilities	-14896	usd
	aimd	Payments Of Lease Liabilities PaymentsOfLeaseLiabilities	-6815	usd
	aimd	Proceeds From Convertible Notes Payable Non Current ProceedsFromConvertibleNotesPayableNonCurrent	1400000	usd
	aimd	Proceeds From Convertible Notes Payable Non Current ProceedsFromConvertibleNotesPayableNonCurrent	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1232192	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	800000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-129405	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
	aimd	Net Proceeds From Uplisting In Nasdaq NetProceedsFromUplistingInNasdaq	1780204	usd
	aimd	Total Payments TotalPayments	0	usd
	aimd	Total Payments TotalPayments	62723	usd
	aimd	Acquisition Of Property And Equipment AcquisitionOfPropertyAndEquipment	575567	usd
	aimd	Acquisition Of Property And Equipment AcquisitionOfPropertyAndEquipment	0	usd
	aimd	Increase In Prepaid For Equipments IncreaseInPrepaidForEquipments	33776	usd
	aimd	Net Proceeds From Uplisting In Nasdaq NetProceedsFromUplistingInNasdaq	0	usd
	aimd	Proceeds From Exercise Of Share Options ProceedsFromExerciseOfShareOptions	0	usd
	aimd	Proceeds From Exercise Of Share Options ProceedsFromExerciseOfShareOptions	64752	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3835903	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1290129	usd
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	99435	usd
	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	7047	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	665648	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	684686	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1751499	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22245	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2417147	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	706931	usd
	us-gaap	Interest Paid Net InterestPaidNet	1872	usd
	us-gaap	Interest Paid Net InterestPaidNet	9363	usd
	aimd	Stock Issued For Compensation Warrant And Option Expense StockIssuedForCompensationWarrantAndOptionExpense	0	usd
	aimd	Stock Issued For Compensation Warrant And Option Expense StockIssuedForCompensationWarrantAndOptionExpense	346938	usd
	aimd	Stock Issued For Acquisition Of Patents StockIssuedForAcquisitionOfPatents	0	usd
	aimd	Stock Issued For Acquisition Of Patents StockIssuedForAcquisitionOfPatents	20000000	usd
	aimd	Issuance Of Convertible Notes For Payables Related Party IssuanceOfConvertibleNotesForPayablesRelatedParty	26000000	usd
	aimd	Issuance Of Convertible Notes For Payables Related Party IssuanceOfConvertibleNotesForPayablesRelatedParty	0	usd
	aimd	Conversion Of Convertible Notes And Accrued Interest Into Common Stock ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock	30442959	usd
	aimd	Conversion Of Convertible Notes And Accrued Interest Into Common Stock ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock	0	usd
	aimd	Increase In Prepaid For Equipments IncreaseInPrepaidForEquipments	0	usd
	aimd	Decrease In Prepaid For Equipments DecreaseInPrepaidForEquipments	60449	usd
	aimd	Decrease In Prepaid For Equipments DecreaseInPrepaidForEquipments	0	usd
	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	669792	usd
	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	0	usd
	aimd	Underwritten Public Offering UnderwrittenPublicOffering	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. </strong><strong>Underwritten Public Offering</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s registration statement related to its underwritten public offering (“Offering”) was declared effective on August 8, 2022, and the Company’s common stock and warrants began trading on the Nasdaq Capital Market (“Nasdaq”) on August 9, 2022 under the trading symbols “AIMD” and “AIMDW”, respectively. The Company completed its underwritten public offering of an aggregated 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the Offering, the Company’s board of directors on April 29, 2022 and our shareholders on May 16, 2022 approved a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and each series of its redeemable convertible notes to be consummated prior to the effectiveness of the Offering The par value and authorized shares of the Company’s common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock, RSUs, warrants and options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the Reverse Stock Split for all periods presented.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company filed an amended Restated Certificate of Formation with the Secretary of State of Texas on August 8, 2022 that effectuated the Reverse Stock Split.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additional information regarding the Offering and Reverse Stock Split can be found below in Note 5 of the Notes to Financial Statements.</p>
CY2022Q3	us-gaap	Shares Issued SharesIssued	780000	shares
CY2022Q3	aimd	Exercise Price Of Share ExercisePriceOfShare	425000	usd
CY2022Q3	us-gaap	Preferred Units Offering Costs PreferredUnitsOfferingCosts	425000	usd
CY2022Q3	aimd	Convertible Debts ConvertibleDebts	145066	usd
	aimd	Warrant Conversion WarrantConversion	966174	shares
	us-gaap	Proceeds From Decommissioning Fund ProceedsFromDecommissioningFund	1800000	usd
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.68
	aimd	Equity Incentive Plans EquityIncentivePlans	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. </strong><strong>Equity Incentive Plans </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>2018 Employee Stock Option Plan (the “2018-ESOP”)</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 26, 2018, the Board adopted the Company 2018 Employee Stock Option Plan (the “2018-ESOP”), formerly referred to as the “Amarillo Biosciences, Inc., 2018 Employee Stock Option Plan” in prior filings. The 2018-ESOP provides for the grant of Qualified Incentive Stock Options to the Company’s employees. Qualified options automatically became non-qualified options effective September 26, 2019 and was governed under the 2018-NQSOP described below because the plan was not ratified by our shareholders. The maximum number of shares of common stock authorized under the plan was 66,666 shares. The option price per share of common stock deliverable upon the exercise of an incentive stock option was 100% of the fair market value of a share on the date of grant. The option price is $5.7 per share and the options are exercisable during a period of ten years from the date of grant, where the options vest 20% annually over five years, commencing one year from date of grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective as of October 6, 2021, with the adoption by the Board of the 2021 SIP, no further awards may be granted under the 2018-ESOP.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan (the “2018-NQSOP”)</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 26, 2018, the Board adopted the Company 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan (the “2018-NQSOP”), formerly referred to as the “Amarillo Biosciences, Inc., 2018 Officers, Directors, Employees, and Consultants Nonqualified Stock Option Plan” in prior filings. The 2018-NQSOP provides for the grant of nonqualified incentive stock options to employees. The 2018-NQSOP is administered by the Board or by the Compensation Committee as constituted from time to time. The maximum number of shares of common stock which may be issued under the 2018-NQSOP is 266,666 which will be reserved for issuance upon exercise of options. The option price for the nonqualified options is $5.73 exercisable for a period of ten years, with a vesting period of five years at 20% per year commencing one year from date of grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective as of October 6, 2021, with the adoption by the Board of the 2021 SIP, no further awards may be granted under the 2018-NQSOP. As of September 30, 2022, options to acquire 36,666 shares of common stock remained outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>2021 Employee Stock Purchase Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 28, 2021, the Board and on May 16, 2022 our shareholders, respectively, approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP” or “Plan”). The purpose of the 2021 ESPP is to provide an opportunity for eligible employees of the company and its designated companies (as defined in the Plan) to purchase common stock at a discount through voluntary contributions, thereby attracting, retaining and rewarding such persons and strengthening the mutuality of interest between such persons and the Company’s stockholders. The Company intends for offerings under the Plan to qualify as an “employee stock purchase plan” under Section 423 of the Code; provided, that the Plan administrator may also authorize the grant of rights under offerings that are not intended to comply with the requirements of Section 423, pursuant to any rules, procedures, agreements, appendices, or sub-plans adopted by the administrator. Subject to adjustments as provided in the Plan, the maximum number of shares of common stock that may be issued under the Plan may not exceed 50,000 shares. Such shares may be authorized but unissued shares, treasury shares or shares purchased in the open market. The Plan is subject to approval by the Company’s stockholders within twelve months after the date of Board approval. The Plan will become effective on the date that stockholder approval is obtained, and will continue in effect until it expires on the tenth anniversary of the effective date of the Plan, unless terminated earlier.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>2021 Stock Incentive Plan</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 28, 2021, the Board and on May 16, 2022 our shareholders, respectively, approved the 2021 Stock Incentive Plan (the “2021 SIP” or “Plan”). The purpose of the 2021 SIP is to provide a means through which the Company, and the other members of the Company Group, defined by Section 2(n) of the Plan as the Company and its subsidiaries, and any other affiliate of the Company designated as a member of the Company Group by the Committee, may attract and retain key personnel, and to provide a means whereby directors, officers, employees, consultants and advisors of the Company and the other members of the Company Group can acquire and maintain an equity interest in the Company, or be paid incentive compensation measured by reference to the value of common stock, thereby strengthening their commitment to the interests of the Company Group and aligning their interests with those of the Company’s stockholders. The types of awards that may be granted from the Plan include individually or collectively, any Incentive Stock Option, Nonqualified Stock Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Dividend Equivalent Rights and Other Equity-Based Award granted under the Plan. The Plan will be effective upon shareholder approval. The expiration date of the Plan, on and after which date no awards may be granted, will be the tenth anniversary of the date of Board approval of the Plan, provided, however, that such expiration will not affect awards then outstanding, and the terms and conditions of the Plan will continue to apply to such Awards. The aggregate number of shares which may be issued pursuant to awards under the Plan is 1,333,333 shares of Common Stock (the “Plan Share Reserve”), subject to adjustments as provided in the Plan. The number of shares underlying any award granted under 2018 ESOP or 2018 NQSOP (the “Prior Plans”) that expires, terminates or is canceled or forfeited for any reason whatsoever under the terms of the Prior Plans, will increase the Plan Share Reserve. Each Award granted under the Plan will reduce the Plan Share Reserve by the number of shares underlying the award. No more than 666,666 shares may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Plan. The maximum number of shares subject to awards granted during a single fiscal year to any non-employee director, taken together with any cash fees paid to such director during the fiscal year, will not exceed $600,000 in total value (calculating the value of any such awards based on their grant date fair value for financial reporting purposes).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">On July 28, 2022, the Company granted 533,332 and 88,000 Restricted Stock Units (the “RSUs”), after giving effect to the Reverse Stock Split, under the 2021 SIP to employees and non-employee directors, respectively. The RSUs shall vest in accordance to the respective employment agreements entered into by each of the employees and the 2021 Non-employee Director Compensation Policy relative to the non-employee directors.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Restricted Stock Units</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">RSUs entitle the recipient to be paid out an equal number of common stock shares upon vesting. The fair value of RSUs is based on market price of the underlying stock on the date of grant. A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2022 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of RSUs</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted-</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average Grant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date Fair Value </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Per RSU</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balance as of December 31,2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">RSUs granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">621,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">RSUs vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(533,332</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">RSUs canceled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Balance as of September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">88,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11.10</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The aggregate fair value of RSU awards that vested in the three- and nine-month periods ended September 30, 2022 was $1 million. The grant date fair value of awards that vested in the three- and nine-month periods ended September 30, 2022 was $5.9 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Warrants</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, following warrants are outstanding:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the Offering on August 9, 2022, the Company issued 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to an underwriting agreement, dated August 8, 2022, by and between the Company and Maxim Group LLC (“Maxim”), as representative of the underwriters, Maxim partially exercised the option to purchase 117,000 additional warrants at a price per warrant of $0.01.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the underwriting agreement the Company issued representative warrants to the Maxim, as representative of the underwriters, to purchase 39,000 shares of common stock at an exercise price of $4.675, effective from February 5, 2023 until August 8, 2027.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 25, 2020, the Company issued a warrant to i2China Management Group, LLC, a related party of the Company since August 1, 2021. The warrant entitles the holder to purchase 30,174 shares $3.98 and expires on November 24, 2025. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Share-Based Compensation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The share-based compensation for the three months ended September 30, 2022 and 2021 were $6,076,017 and $19,322, respectively; and compensation for the nine months ended September 30, 2022 and 2021 were $6,162,902 and $ 207,533, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, the total unrecognized compensation cost related to outstanding RSUs, stock options and warrant was $1,197,230, which the Company expects to recognize over a weighted-average period of 1.61 years.</p>
CY2022Q3	aimd	Aggregate Fair Value Of Rsu AggregateFairValueOfRsu	1000000	usd
CY2022Q3	aimd	Grant Date Fair Value GrantDateFairValue	5900000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	6076017	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	19322	usd
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	6162902	usd
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	207533	usd
CY2022Q3	aimd	Unrecognised Stock Options And Warrants UnrecognisedStockOptionsAndWarrants	1197230	usd
CY2022Q1	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	3000000	usd
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	800000	usd
	srt	Interest Bearing Liabilities Average Rate Paid InterestBearingLiabilitiesAverageRatePaid	0.0185	pure
CY2022Q3	us-gaap	Other Notes Payable OtherNotesPayable	3042959	usd
CY2022Q3	aimd	Converted Shares Of Common Stock ConvertedSharesOfCommonStock	1014319	usd
CY2022Q3	us-gaap	Other Notes Payable OtherNotesPayable	1260526	usd
	us-gaap	Interest Expense InterestExpense	44674	usd
	us-gaap	Interest Expense InterestExpense	32775	usd
CY2022Q3	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	28517	usd
CY2021Q4	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	28673	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	26000000	usd
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1400000	usd
	aimd	Non Current Convertible Notes Payable NonCurrentConvertibleNotesPayable	27400000	usd
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	8058818	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6666666	shares
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3
CY2021Q2	aimd	Common Stock Authorized CommonStockAuthorized	300000000	shares
CY2021Q2	aimd	Issued And Outstanding Shares Of Common Stock Ownership Percentage IssuedAndOutstandingSharesOfCommonStockOwnershipPercentage	0.7030	pure
CY2022Q3	aimd	Repurchase Agreements Interest Expense Amount1 RepurchaseAgreementsInterestExpenseAmount1	26000000	usd

Files In Submission

Name	View Source	Status
0001654954-22-015091-index-headers.html	Edgar Link	pending
0001654954-22-015091-index.html	Edgar Link	pending
0001654954-22-015091.txt	Edgar Link	pending
0001654954-22-015091-xbrl.zip	Edgar Link	pending
aimd-20220930.xsd	Edgar Link	pending
aimd_10q.htm	Edgar Link	pending
aimd_ex311.htm	Edgar Link	pending
aimd_ex312.htm	Edgar Link	pending
aimd-20220930_cal.xml	Edgar Link	unprocessable
aimd-20220930_def.xml	Edgar Link	unprocessable
aimd-20220930_pre.xml	Edgar Link	unprocessable
aimd-20220930_lab.xml	Edgar Link	unprocessable
aimd_10q_htm.xml	Edgar Link	completed
aimd_ex321.htm	Edgar Link	pending
aimd_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIMD
Ainos, Inc. Stock $aimd

2022 Q4 Form 10-Q Financial Statement

#000165495422015091 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIMD Ainos, Inc. Stock $aimd

2022 Q4 Form 10-Q Financial Statement

#000165495422015091 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIMD
Ainos, Inc. Stock $aimd